Aurinia Pharmaceuticals Inc. (AUPH)
After hours:
| Previous close | 5.16 |
| Open | 5.26 |
| Bid | 5.36 x 600 |
| Ask | 5.39 x 700 |
| Day's range | 5.22 - 5.43 |
| 52-week range | 4.71 - 12.43 |
| Volume | |
| Avg. volume | 1,440,179 |
| Market cap | 769.442M |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
ROCKVILLE, Md. & EDMONTON, Alberta, May 30, 2024--Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
- Business Wire
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 14, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program.
- Business Wire
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 09, 2024--Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
